Medivation Announces Presentation Of Full Top-Line Data From Dimebon(TM) Six-Month Trial At Major International Alzheimer's Disease Conference

Medivation, Inc.
(Amex: MDV) today announced that six-month results from its randomized,
double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in
patients with mild-to-moderate Alzheimer's disease demonstrated that
patients treated with Dimebon were significantly improved compared to
patients taking placebo on all five efficacy endpoints studied, which
assessed cognitive function, memory, ability to perform tasks of daily
living, global function and behavior.


Full top-line data from this trial were presented yesterday for the
first time as an oral presentation (abstract #1662) at the 8th
International Conference on Alzheimer's and Parkinson's Diseases: Progress
and New Perspectives, in Salzburg, Austria, by the study's lead
investigator, Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair in
Alzheimer's Disease Research at the Alzheimer's Disease and Memory
Disorders Center, Baylor College of Medicine in Houston.



New data presented in Salzburg included the magnitude and levels of
statistical significance by which the Dimebon-treated patients outperformed
the placebo-treated patients on the Mini Mental State Exam (MMSE:
p